Arkolith/Insider Trading/GANX/Form 4

Alder Matthias

Chief Executive Officer, DirectorGain Therapeutics, Inc. (GANX) · full profile →Form 4 · filed Mar 28, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 26, 2024Tax withholding(F)6K$4.06$25K21K
Mar 26, 2024Option exercise(M)825——27K
Mar 26, 2024Option exercise(M)19K——26K
Mar 26, 2024Option exercise(M)637——27K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 26, 2024Option exercise(M)825—$08K
Mar 26, 2024Option exercise(M)19K—$056K
Mar 26, 2024Option exercise(M)637—$06K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-24-011836) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Gain Therapeutics, Inc.

Build

Ask your agent about GANX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001493152-24-011836"
Ask your agent
Use Arkolith to summarize insider buying and selling at Gain Therapeutics, Inc.
over the last 90 days and cite the filings.